子類別 期刊論文 [32/32] 會議論文/會議摘要 [8/8] 鄰近社群 于重元 [19/19] 劉柯俊 [85/98] 劉滄梧 [119/125] 劉界元(2003-2010) [3/3] 夏和雄(1996-2012) [26/31] 夏興國 [51/54] 姜乃榕 [82/94] 常慧如 [39/44] 張俊彥 [234/254] 張光裕 [69/79] 張憶壽 [103/106] 張文祥 [52/53] 張書銘 [89/91] 彭汪嘉康(1996-2007) [120/126] 施能耀 [37/43] 李家惠 [29/29] 李岳倫 [48/49] 林素芳 [32/32] 楊奕馨 [41/42] 江士昇 [88/90] 沈哲宏 [14/16] 洪文俊 [88/88] 莊雙恩 [82/91] 蔡坤志 [32/34] 蔡慧珍 [66/71] 蘇振良 [24/25] 郭靜娟 [71/76] 陳尚鴻 [45/48] 陳振陽 [72/72] 陳立宗 [443/510] 陳美霞(2002-2009) [1/1] 陳詩政 [2/2] 陳雅雯 [38/39] 黃智興 [55/55] 黃道揚 [26/26] 丁兆治(2000-2004) [5/5] 其他 [464/471] 劉敏(1996-2007) [60/62] 劉玫英(2004-2006) [2/2] 吳成文(1996-2008) [53/55] 曾思文(1997-2007) [4/4] 李冠德(1997-2004) [4/6] 林景太(1999-2007) [5/5] 楊文光(1996-1999) [21/21] 王全正(1996-2003) [4/4] 莊聲宏(1997-2004) [11/11] 詹宗晃(2000-2008) [2/2] 賴基銘(2004-2008) [41/47] 阮麗蓉(2000-2006) [6/7] 陳俊叡(2003-2007) [6/6] 馬彥英(1997-1999) [1/1] 黃奇英(2005-2007) [9/10] 社群統計 近3年內發表的文件:32(80.00%) 含全文筆數:40(100.00%) 文件下載次數統計 下載大於0次:40(100.00%) 下載大於100次:31(77.50%) 檔案下載總次數:6601(0.12%) 最後更新時間: 2024-12-01 15:27 上傳排行 資料載入中..... 下載排行 資料載入中..... 最近上傳 Pathological response following neo... Clinical outcomes and histologic fi... Cytoplasmic lipid droplets predict ... A phase 1 study of biweekly nab-pac... Outcomes of post-immunotherapy dura... Impact of previous S-1 treatment on... Neuron-derived neurotensin promotes... Germline mutations of homologous re... Systemic treatments in pancreatic c... Single-cell RNA sequencing via Endo...

跳至: (選擇年份) 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1985 1980 1975 1970 1960 1950 (選擇月份) January February March April May June July August September October November December 或輸入年份:

由新到舊排序 由最舊的開始

顯示項目1-40 / 40. (共1頁) 1  每頁顯示[10|25|50]項目

日期	題名	關聯
2024-11	Cytoplasmic lipid droplets predict worse prognosis in diffuse large B-cell lymphoma: Next-generation sequencing deciphering lipogenic genes	American Journal of Surgical Pathology. 2024 Nov 1;48(11):1425-1438.
2024-11	Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: A cross-trial, patient-level analysis	Lancet. Oncology. 2024 Nov;25(11):1465-1475.
2024-10	A phase 1 study of biweekly nab-paclitaxel/oxaliplatin/S-1/LV for advanced upper gastrointestinal cancers: TCOG T1216 study	Oncologist. 2024 Oct 3;29(10):e1396-e1405.
2024-08-28	Clinical outcomes and histologic findings of patients with hepatocellular carcinoma with durable partial response or durable stable disease after receiving atezolizumab plus bevacizumab	Journal of Clinical Oncology. 2024 Aug 28;Article in Press.
2024-06	Systemic treatments in pancreatic cancer: Taiwan pancreas society recommendation	Biomedical Journal. 2024 Jun;47(3):Article number 100696.
2024-05	Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer	Pancreatology. 2024 May;24(3):600-607.
2024-02-15	Neuron-derived neurotensin promotes pancreatic cancer invasiveness and gemcitabine resistance via the NTSR1/Akt pathway	American Journal of Cancer Research. 2024 Feb 15;14(2):448-466.
2024-02-13	Germline mutations of homologous recombination genes and clinical outcomes in pancreatic cancer: A multicenter study in Taiwan	Journal of Biomedical Science. 2024 Feb 13;31:Article number 21.
2024-02-01	Outcomes of post-immunotherapy durable responders of advanced hepatocellular carcinoma- with emphasis on locoregional therapy for oligoprogression	Liver Cancer. 2024 Feb 01;Article in Press.
2023-11	Nivolumab plus ipilimumab (N plus I) for potentially resectable hepatocellular carcinoma (HCC): Efficacy and surgical outcome	Annals of Oncology. 2023 Nov;34(Suppl. 3):S1390.
2023-11	Single-cell RNA sequencing via Endoscopic Ultrasoundguided Fine-Needle Biopsy (EUS-FNB) Pancreatic Biopsies uncovered an aggressive subclone with a poor prognosis	Annals of Oncology. 2023 Nov;34(Suppl. 4):S1536-S1537.
2023-09-01	The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer. a cross sectional study	International Journal of Surgery. 2023 Sep 1;109(9):2614-2623.
2023-08-15	Pancreatic cancer cell-derived semaphorin 3A promotes neuron recruitment to accelerate tumor growth and dissemination	American Journal of Cancer Research. 2023 Aug 15;13(8):3417-3432.
2023-06	Investigation into the content of red material in EUS-guided pancreatic cancer biopsies	Gastrointestinal Endoscopy. 2023 Jun;97(6):1083-1091.e1.
2023-06	Aristolochic acid (AA) exposure and telomere maintenance mechanism in liver angiosarcoma (AS)	Journal of Clinical Oncology. 2023 Jun;41(16 Suppl.):Meeting Abstract 11551.
2023-03	Tissue quality comparison between heparinized wet suction and dry suction in endoscopic ultrasound-fine needle biopsy of solid pancreatic masses: A randomized crossover study	Gut and Liver. 2023 Mar 15;17(2):318-327.
2023-02-05	Real-world data validation of NAPOLI-1 nomogram for the prediction of overall survival in metastatic pancreatic cancer	Cancers. 2023 Feb 5;15(4):Article number 1008.
2023-02	The association between UGT1A1 polymorphisms and treatment toxicities of liposomal irinotecan	ESMO Open. 2023 Feb;8(1):Article number 100746.
2022-11-15	The impact of starting dose with or without subsequent dose escalation of liposomal irinotecan on treatment outcomes in patients with metastatic pancreatic ductal adenocarcinoma	American Journal of Cancer Research. 2022 Nov 15;12(11):5062-5073.
2022-10	Impaired chromatin remodeling predicts better survival to modified gemcitabine and S-1 plus nivolumab in advanced biliary tract Cancer: A phase II T1219 study	Clinical Cancer Research. 2022 Oct 3;28(19):4248-4257.
2022-10	Outcomes of post-immunotherapy durable responders of advanced hepatocellular carcinoma - with emphasis on locoregional therapy for oligoprogression	Hepatology. 2022 Oct;76(Suppl.1):S1411-S1412.
2022-09-21	Clustering of chromatin remodeling enzymes predicts prognosis and clinical benefit of therapeutic strategy in pancreatic cancer	International Journal of Medical Sciences. 2022 Sep 21;19(10):1615-1627.
2022-07	Improved survival with neoadjuvant chemotherapy in stage III pancreatic cancer: A single institutional experience	Annals of Oncology. 2022 Jul;33(Suppl. 6):S535.
2022-07	Potential roles of gut microbiome in patients with hepatocellular carcinoma treated with immune checkpoint inhibitors	Annals of Oncology. 2022 Jul;33(Suppl. 6):S484.
2022-07	A phase II trial of nivolumab, gemcitabine and S-1 as the frst-line treatment in patients with biliary tract cancer	Annals of Oncology. 2022 Jul;33(Suppl. 6):S478.
2022-06-22	Dosing pattern and early cumulative dose of liposomal irinotecan in metastatic pancreatic cancer: A real-world multicenter study	Frontiers in Oncology. 2022 Jun 22;12:Article number 800842.
2022-06-02	Trial Designs for integrating novel therapeutics into the management of intermediate-stage hepatocellular carcinoma	Journal of Hepatocellular Carcinoma. 2022 Jun 2;9:517-536.
2022-06	Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorin	Journal of Hepato-Biliary-Pancreatic Sciences. 2022 Jun;54(5):607-612.
2022-05-15	Improved survival with induction chemotherapy and conversion surgery in locally advanced unresectable pancreatic cancer: A single institution experience	American Journal of Cancer Research. 2022 May 15;12(5):2189-2202.
2022-04-15	The impact of spleen volume on the survival of metastatic pancreatic adenocarcinoma patients receiving nanoliposomal irinotecan	American Journal of Cancer Research. 2022 Apr 15;12(4):1884-1898.
2022-04	A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative Oncology Group T2212 study	British Journal of Cancer. 2022 Apr;126(7):1018-1026.
2022-02-24	Semaphorin 6C suppresses proliferation of pancreatic cancer cells via inhibition of the AKT/GSK3/beta-catenin/cyclin D1 pathway	International Journal of Molecular Sciences. 2022 Feb 24;23(5):Article number 2608.
2021-11-20	Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients’ experience within a population-based study	Therapeutic Advances in Medical Oncology. 2021 Nov 20;Article in Press.
2021-09	A phase II trial of nivolumab and gemcitabine and S-1 as the first-line treatment in patients with advanced biliary tract cancer	Annals of Oncology. 2021 Sep;32(Suppl. 5):S377.
2021-08	Adjuvant versus neoadjuvant immunotherapy for hepatocellular carcinoma: Clinical and immunologic perspectives	Seminars in Liver Disease. 2021 Aug;41(3):263-276.
2020-12-29	Modified gemcitabine, S-1, and leucovorin combination for patients with newly diagnosed locally advanced or metastatic pancreatic adenocarcinoma: A multi-center retrospective study in Taiwan	PLoS ONE. 2020 Dec 29;15(12):Article number e0244487.
2020-11-13	The impact of liposomal irinotecan on the treatment of advanced pancreatic adenocarcinoma: Real-world experience in a Taiwanese cohort [Erraturm: Scientific Reports. 2020 May 4;10:Article number 7420.]	Scientific Reports. 2020 Nov 13;10:Article number 20199.
2020-10	Multicentre, phase II study of gemcitabine and S-1 in patients with advanced biliary tract cancer: TG1308 study	Liver International. 2020 Oct;40(10):2535-2543.
2020-05-04	The impact of liposomal irinotecan on the treatment of advanced pancreatic adenocarcinoma: Real-world experience in a Taiwanese cohort	Scientific Reports. 2020 May 4;10:Article number 7420.
2019-10-05	Percutaneous computed tomography-guided coaxial core biopsy for the diagnosis of pancreatic tumors	Journal of Clinical Medicine. 2019 Oct 5;8(10):Article number 1633.

顯示項目1-40 / 40. (共1頁) 1  每頁顯示[10|25|50]項目